Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


Our top-notch dedicated system is used to design specialised libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
Q6GTS8

UPID:
P20D1_HUMAN

ALTERNATIVE NAMES:
Peptidase M20 domain-containing protein 1

ALTERNATIVE UPACC:
Q6GTS8; Q6P4E3; Q96DM4

BACKGROUND:
The enzyme PM20D1, known for its secretory nature, is integral in maintaining the balance of N-fatty acyl amino acids in tissues and circulation. By facilitating the synthesis and hydrolysis of NAAs, PM20D1 indirectly influences whole-body energy expenditure and metabolic rates, operating independently of UPC1. Its association with lipoprotein particles further underscores its systemic impact.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of PM20D1 offers a promising avenue for novel therapeutic interventions. Given its crucial role in metabolic pathways and energy balance, targeting PM20D1 could lead to breakthroughs in treating metabolic diseases and optimizing energy expenditure.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.